Barclays PLC boosted its stake in Xencor Inc (NASDAQ:XNCR) by 39.1% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,960 shares of the biopharmaceutical company’s stock after buying an additional 2,518 shares during the quarter. Barclays PLC’s holdings in Xencor were worth $269,000 at the end of the most recent quarter.
A number of other hedge funds also recently added to or reduced their stakes in the business. BVF Inc. IL bought a new position in shares of Xencor during the 1st quarter valued at $27,042,000. Artal Group S.A. raised its holdings in shares of Xencor by 200.0% during the 1st quarter. Artal Group S.A. now owns 300,000 shares of the biopharmaceutical company’s stock valued at $8,994,000 after purchasing an additional 200,000 shares in the last quarter. Redmile Group LLC raised its holdings in shares of Xencor by 12.5% during the 4th quarter. Redmile Group LLC now owns 1,350,894 shares of the biopharmaceutical company’s stock valued at $29,612,000 after purchasing an additional 150,600 shares in the last quarter. Farallon Capital Management LLC bought a new position in shares of Xencor during the 1st quarter valued at $4,494,000. Finally, ArrowMark Colorado Holdings LLC raised its holdings in shares of Xencor by 32.9% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 583,491 shares of the biopharmaceutical company’s stock valued at $12,790,000 after purchasing an additional 144,319 shares in the last quarter. Institutional investors own 79.54% of the company’s stock.
In related news, major shareholder John S. Stafford III sold 92,779 shares of the firm’s stock in a transaction on Wednesday, June 20th. The shares were sold at an average price of $40.05, for a total value of $3,715,798.95. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John J. Kuch sold 25,000 shares of the firm’s stock in a transaction on Wednesday, June 13th. The shares were sold at an average price of $41.64, for a total transaction of $1,041,000.00. The disclosure for this sale can be found here. Insiders sold a total of 221,546 shares of company stock worth $8,926,527 over the last quarter. 4.70% of the stock is currently owned by company insiders.
Xencor opened at $39.05 on Friday, Marketbeat Ratings reports. Xencor Inc has a 1 year low of $18.97 and a 1 year high of $43.39. The firm has a market capitalization of $2.07 billion, a P/E ratio of -37.19 and a beta of 1.64.
Xencor (NASDAQ:XNCR) last posted its earnings results on Monday, May 7th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.16). Xencor had a negative net margin of 137.35% and a negative return on equity of 18.07%. equities analysts anticipate that Xencor Inc will post -2.33 earnings per share for the current fiscal year.
XNCR has been the topic of a number of recent research reports. ValuEngine upgraded shares of Xencor from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Cantor Fitzgerald restated a “buy” rating and set a $37.00 price target on shares of Xencor in a report on Thursday, March 29th. Canaccord Genuity raised their price target on shares of Xencor from $36.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, May 9th. BTIG Research initiated coverage on shares of Xencor in a report on Thursday, June 7th. They set a “buy” rating and a $56.00 price target on the stock. Finally, BidaskClub downgraded shares of Xencor from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 30th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $37.88.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.